Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant

Neal J. Meropol, Robert A. Somer, John Gutheil, Robert J. Pelley, Manuel R. Modiano, Eric K. Rowinsky, Mace L. Rothenberg, Spencer W. Redding, Cuneyt M. Serdar, Bin Yao, Robert Heard, Lee S. Rosen

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Purpose: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer. Patients and Methods: Patients (N = 81 ) received KGF by intravenous (IV) bolus on days 1 to 3, followed by FU 425 mg/m 2/d IV bolus plus leucovorin 20 mg/m2/d IV on days 4 to 8. KGF dose levels were 1, 10, 20, 40, 60, and 80 μg/kg/d. A randomized, placebo-controlled design was employed (2:1 randomization of KGF to placebo). Oral mucositis was assessed by examination on days 1, 4, 8, 15, and 28. In addition, patients provided daily assessments of oral symptoms using a self-administered questionnaire. Results: Skin and oral events occurred in 13 of 18 patients (eight patients, grade 1; four patients, grade 2; and one patient, grade 3) treated with 60 and 80 μg/kg of KGF and three of 11 patients treated with 40 μg/kg (grade 1). These symptoms were dose limiting in three cases (ie, in two of 10 patients treated with 80 μg/kg and in one of eight patients treated with 60 μg/kg). The frequency of grade 2 to 4 mucositis was 43% in patients treated with KGF, compared with 67% in patients treated with placebo (P = .06). Patient self-assessments of oral pain and clinical assessments of mucositis showed good correlation (Kendall's tau = 0.75). Conclusion: KGF is generally well tolerated when administered IV at doses up to 40 μg/kg/d for 3 days before a 5-day course of FU plus leucovorin. A clinically meaningful biologic effect was also suggested in that patients treated with the epithelial growth factor KGF had a lower rate of grade 2 to 4 mucositis than did patients treated with placebo.

Original languageEnglish (US)
Pages (from-to)1452-1458
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number8
DOIs
StatePublished - Apr 15 2003
Externally publishedYes

Fingerprint

Drug Therapy
Fibroblast Growth Factor 7
Mucositis
Placebos
Fluorouracil
Leucovorin
human FGF7 protein
Stomatitis
Symptom Assessment
Pain Measurement
Random Allocation
Colorectal Neoplasms
Intercellular Signaling Peptides and Proteins
Safety
Skin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Meropol, N. J., Somer, R. A., Gutheil, J., Pelley, R. J., Modiano, M. R., Rowinsky, E. K., ... Rosen, L. S. (2003). Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant. Journal of Clinical Oncology, 21(8), 1452-1458. https://doi.org/10.1200/JCO.2003.10.079

Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy : Potential role as mucosal protectant. / Meropol, Neal J.; Somer, Robert A.; Gutheil, John; Pelley, Robert J.; Modiano, Manuel R.; Rowinsky, Eric K.; Rothenberg, Mace L.; Redding, Spencer W.; Serdar, Cuneyt M.; Yao, Bin; Heard, Robert; Rosen, Lee S.

In: Journal of Clinical Oncology, Vol. 21, No. 8, 15.04.2003, p. 1452-1458.

Research output: Contribution to journalArticle

Meropol, NJ, Somer, RA, Gutheil, J, Pelley, RJ, Modiano, MR, Rowinsky, EK, Rothenberg, ML, Redding, SW, Serdar, CM, Yao, B, Heard, R & Rosen, LS 2003, 'Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant', Journal of Clinical Oncology, vol. 21, no. 8, pp. 1452-1458. https://doi.org/10.1200/JCO.2003.10.079
Meropol, Neal J. ; Somer, Robert A. ; Gutheil, John ; Pelley, Robert J. ; Modiano, Manuel R. ; Rowinsky, Eric K. ; Rothenberg, Mace L. ; Redding, Spencer W. ; Serdar, Cuneyt M. ; Yao, Bin ; Heard, Robert ; Rosen, Lee S. / Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy : Potential role as mucosal protectant. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 8. pp. 1452-1458.
@article{cd1b7262b3374fd2af6210fb60d77dd8,
title = "Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant",
abstract = "Purpose: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer. Patients and Methods: Patients (N = 81 ) received KGF by intravenous (IV) bolus on days 1 to 3, followed by FU 425 mg/m 2/d IV bolus plus leucovorin 20 mg/m2/d IV on days 4 to 8. KGF dose levels were 1, 10, 20, 40, 60, and 80 μg/kg/d. A randomized, placebo-controlled design was employed (2:1 randomization of KGF to placebo). Oral mucositis was assessed by examination on days 1, 4, 8, 15, and 28. In addition, patients provided daily assessments of oral symptoms using a self-administered questionnaire. Results: Skin and oral events occurred in 13 of 18 patients (eight patients, grade 1; four patients, grade 2; and one patient, grade 3) treated with 60 and 80 μg/kg of KGF and three of 11 patients treated with 40 μg/kg (grade 1). These symptoms were dose limiting in three cases (ie, in two of 10 patients treated with 80 μg/kg and in one of eight patients treated with 60 μg/kg). The frequency of grade 2 to 4 mucositis was 43{\%} in patients treated with KGF, compared with 67{\%} in patients treated with placebo (P = .06). Patient self-assessments of oral pain and clinical assessments of mucositis showed good correlation (Kendall's tau = 0.75). Conclusion: KGF is generally well tolerated when administered IV at doses up to 40 μg/kg/d for 3 days before a 5-day course of FU plus leucovorin. A clinically meaningful biologic effect was also suggested in that patients treated with the epithelial growth factor KGF had a lower rate of grade 2 to 4 mucositis than did patients treated with placebo.",
author = "Meropol, {Neal J.} and Somer, {Robert A.} and John Gutheil and Pelley, {Robert J.} and Modiano, {Manuel R.} and Rowinsky, {Eric K.} and Rothenberg, {Mace L.} and Redding, {Spencer W.} and Serdar, {Cuneyt M.} and Bin Yao and Robert Heard and Rosen, {Lee S.}",
year = "2003",
month = "4",
day = "15",
doi = "10.1200/JCO.2003.10.079",
language = "English (US)",
volume = "21",
pages = "1452--1458",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy

T2 - Potential role as mucosal protectant

AU - Meropol, Neal J.

AU - Somer, Robert A.

AU - Gutheil, John

AU - Pelley, Robert J.

AU - Modiano, Manuel R.

AU - Rowinsky, Eric K.

AU - Rothenberg, Mace L.

AU - Redding, Spencer W.

AU - Serdar, Cuneyt M.

AU - Yao, Bin

AU - Heard, Robert

AU - Rosen, Lee S.

PY - 2003/4/15

Y1 - 2003/4/15

N2 - Purpose: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer. Patients and Methods: Patients (N = 81 ) received KGF by intravenous (IV) bolus on days 1 to 3, followed by FU 425 mg/m 2/d IV bolus plus leucovorin 20 mg/m2/d IV on days 4 to 8. KGF dose levels were 1, 10, 20, 40, 60, and 80 μg/kg/d. A randomized, placebo-controlled design was employed (2:1 randomization of KGF to placebo). Oral mucositis was assessed by examination on days 1, 4, 8, 15, and 28. In addition, patients provided daily assessments of oral symptoms using a self-administered questionnaire. Results: Skin and oral events occurred in 13 of 18 patients (eight patients, grade 1; four patients, grade 2; and one patient, grade 3) treated with 60 and 80 μg/kg of KGF and three of 11 patients treated with 40 μg/kg (grade 1). These symptoms were dose limiting in three cases (ie, in two of 10 patients treated with 80 μg/kg and in one of eight patients treated with 60 μg/kg). The frequency of grade 2 to 4 mucositis was 43% in patients treated with KGF, compared with 67% in patients treated with placebo (P = .06). Patient self-assessments of oral pain and clinical assessments of mucositis showed good correlation (Kendall's tau = 0.75). Conclusion: KGF is generally well tolerated when administered IV at doses up to 40 μg/kg/d for 3 days before a 5-day course of FU plus leucovorin. A clinically meaningful biologic effect was also suggested in that patients treated with the epithelial growth factor KGF had a lower rate of grade 2 to 4 mucositis than did patients treated with placebo.

AB - Purpose: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer. Patients and Methods: Patients (N = 81 ) received KGF by intravenous (IV) bolus on days 1 to 3, followed by FU 425 mg/m 2/d IV bolus plus leucovorin 20 mg/m2/d IV on days 4 to 8. KGF dose levels were 1, 10, 20, 40, 60, and 80 μg/kg/d. A randomized, placebo-controlled design was employed (2:1 randomization of KGF to placebo). Oral mucositis was assessed by examination on days 1, 4, 8, 15, and 28. In addition, patients provided daily assessments of oral symptoms using a self-administered questionnaire. Results: Skin and oral events occurred in 13 of 18 patients (eight patients, grade 1; four patients, grade 2; and one patient, grade 3) treated with 60 and 80 μg/kg of KGF and three of 11 patients treated with 40 μg/kg (grade 1). These symptoms were dose limiting in three cases (ie, in two of 10 patients treated with 80 μg/kg and in one of eight patients treated with 60 μg/kg). The frequency of grade 2 to 4 mucositis was 43% in patients treated with KGF, compared with 67% in patients treated with placebo (P = .06). Patient self-assessments of oral pain and clinical assessments of mucositis showed good correlation (Kendall's tau = 0.75). Conclusion: KGF is generally well tolerated when administered IV at doses up to 40 μg/kg/d for 3 days before a 5-day course of FU plus leucovorin. A clinically meaningful biologic effect was also suggested in that patients treated with the epithelial growth factor KGF had a lower rate of grade 2 to 4 mucositis than did patients treated with placebo.

UR - http://www.scopus.com/inward/record.url?scp=0037842184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037842184&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.10.079

DO - 10.1200/JCO.2003.10.079

M3 - Article

C2 - 12697866

AN - SCOPUS:0037842184

VL - 21

SP - 1452

EP - 1458

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -